Istradefylline reduces memory deficits in aging mice with amyloid pathology

Istradefylline reduces memory deficits in aging mice with amyloid pathology

Adenosine A2A receptors are putative therapeutic targets for neurological disorders. The adenosine A2A receptor antagonist istradefylline is approved in Japan for Parkinson's disease and is being tested in clinical trials for this condition elsewhere. A2A receptors on neurons and astrocytes may...

Full description

Bibliographic Details
Main Authors: Anna G. Orr, Iris Lo, Heike Schumacher, Kaitlyn Ho, Michael Gill, Weikun Guo, Daniel H. Kim, Anthony Knox, Takashi Saito, Takaomi C. Saido, Jeffrey Simms, Carlee Toddes, Xin Wang, Gui-Qiu Yu, Lennart Mucke
Format: Article
Language:English
Published: Elsevier 2018-02-01
Series:Neurobiology of Disease
Subjects:
Adenosine receptors
Alzheimer's disease
Amyloid plaques
Antagonist
Astrocytes
Behavior
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996117302413

Internet

http://www.sciencedirect.com/science/article/pii/S0969996117302413

Similar Items